Oncology Nursing News magazine interviewed Carl Harrington, president of the IWMF, about the US FDA's decision to approve imbruvica (ibrutinib).
Cure magazine (http://www.curetoday.com) interviewed Carl Harrington, president of the IWMF, to properly present the impact that the US FDA's decision to approve imbruvica (ibrutinib) specifically for WM has on WM patients.
In a history-making moment for WM patients, the IWMF is pleased to announce that Imbruvica (ibrutinib) has just received FDA approval specifically for the treatment of WM, thus becoming the first drug therapy to achieve this designation.
View a recent video presentation by Dr. Mary Lou McMaster to the Northern Virginia IWMF Support Group.
NEW IWMF AFFILIATE/SUPPORT GROUP ESTABLISHED in ITALY